ADC Therapeutics S.A.

NYSE:ADCT

Biotechnology

Healthcare
$1.37 -1.35%

-$0.02 today

Market cap
$192.71M
Beta
1.77
P/E (TTM)
-1.2
EPS (TTM)
-$0.89
52W Low $0.78High $4.98

Volume 1.17M

Average 1.68M

ADCT Income Before Tax

Profit after all operating and non-operating items but before income tax.

ADC Therapeutics S.A.NYSE: ADCT

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$32.97M, compared with -$38.44M a year earlier. Trailing-twelve-month income before tax was -$136.14M.

Context

  • Income before tax amounted to 175.5% of revenue in FY2025, down 47.1 pp from a year earlier.
  • Income before tax grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$32.97M or moves back toward the trailing-twelve-month quarterly average of -$34.03M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$32.97M-383.9% QoQ
Last fiscal yearDec 2025
-$142.78M+9.4% YoY
LTMMar 2026
-$136.14M+9.0% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.2%——
1 year+9.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(142.78M) USD
Year-over-year change
+9.4%

Income Before Tax vs competitors

How ADCT compares with its peers on the latest reported figures

  • ADCT's LTM Mar 2026 income before tax of -$136.14M is the 5th highest of the 10 companies compared; the peer median is -$160.9M.
  • Its year-over-year change of +9.0% is the 4th highest of 10, against a peer median of -3.2%.
  • Income before tax amounts to 171.9% of revenue for ADCT, versus a peer median of 405.8%.
ADCT Competitors Peer median
Income Before Tax for ADCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OMEROmeros CorporationLTM Mar 2026$86.08M +148.8%—870.1%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026-$26.09M +85.3%—37.5%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026-$69.29M -328.6%—468.9%
QSIQuantum-Si incorporatedLTM Mar 2026-$103.9M -3.2%—5609.9%
ADCTADC Therapeutics S.A.LTM Mar 2026-$136.14M +9.0%—171.9%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-$160.9M +8.8%—182.3%
BCYCBicycle Therapeutics plcLTM Mar 2026-$217.62M -4.3%—342.7%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026-$222.34M +13.7%——
AUTLAutolus Therapeutics plcLTM Mar 2026-$288.22M -23.0%—311.3%
ALMSAlumis Inc. Common StockLTM Jun 2026-$440.71M -86.7%—5957.2%
Peer median (excluding ADCT) -$160.9M-3.2%—405.8%

Competitors are the stored peer set for ADCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue33.92M209.91M69.56M70.84M81.36M
Cost of Revenue1.39M3.3M2.53M5.95M7.67M
Gross Profit32.52M206.61M67.03M64.89M73.68M
Gross Margin95.9%98.4%96.4%91.6%90.6%
Research & Development158M186.46M127.13M109.63M104.01M
Selling, General & Admin136.24M143.49M105.89M85.91M(6.82M)
Operating Expenses294.24M329.95M233.02M195.54M182.06M
Depreciation & Amortization2.63M2.39M3.27M3.28M1.88M
EBITDA(230.54M)(107.7M)(145.83M)(102.65M)(89.27M)
EBITDA Margin-679.7%-51.3%-209.6%-144.9%-109.7%
Operating Income(261.72M)(123.34M)(165.99M)(130.65M)(108.38M)
Operating Margin-771.6%-58.8%-238.6%-184.4%-133.2%
Interest Income66K2.57M10.54M12.27M8.81M
Interest Expense18.34M36.73M46.33M50.21M51.63M
Other Income / Expenses10.22M(33.56M)(34.96M)(27.03M)(34.4M)
Income Before Tax(251.51M)(156.9M)(200.95M)(157.68M)(142.78M)
Pre-Tax Margin-741.5%-74.7%-288.9%-222.6%-175.5%
Income Tax Expense(21.48M)227K39.11M166K(157K)
Net Income(230.03M)(157.13M)(240.05M)(157.85M)(142.62M)
Net Margin-678.2%-74.9%-345.1%-222.8%-175.3%
EPS (Basic)(3.00)(1.99)(2.94)(1.62)(1.12)
EPS (Diluted)(3.00)(1.99)(2.94)(1.62)(1.12)
Weighted Avg Shares76.75M78.15M81.71M97.16M127.07M
Weighted Avg Shares (Diluted)76.75M78.15M81.71M97.16M127.07M

ADC Therapeutics S.A.

NYSE:ADCT

Intrinsic Alpha fair value

Locked

Current Price

$1.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.